{"id":"placebo-for-pitavastatin","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is not a drug with a mechanism of action. It is used in randomized controlled trials as a comparator to assess the efficacy and safety of the active drug (in this case, Pitavastatin, a statin). Any observed effects in the placebo group are attributed to the placebo effect or natural disease progression.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:57.801Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07442630","phase":"PHASE4","title":"Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides","status":"ACTIVE_NOT_RECRUITING","sponsor":"JW Pharmaceutical","startDate":"2023-08-21","conditions":"Hypercholesterolemia","enrollment":88},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT02344290","phase":"PHASE3","title":"Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-03-26","conditions":"HIV, Cardiovascular Diseases","enrollment":7769},{"nctId":"NCT03070223","phase":"PHASE3","title":"PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2017-03-14","conditions":"HIV-1 Infection","enrollment":602},{"nctId":"NCT02799758","phase":"PHASE3","title":"Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia","status":"WITHDRAWN","sponsor":"Kowa Research Institute, Inc.","startDate":"2016-02","conditions":"Hyperlipidemia, Dyslipidemia","enrollment":""},{"nctId":"NCT02670434","phase":"PHASE3","title":"Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia","status":"WITHDRAWN","sponsor":"Kowa Research Institute, Inc.","startDate":"2016-01","conditions":"Hyperlipidemia, Dyslipidemia","enrollment":""},{"nctId":"NCT04705909","phase":"PHASE2, PHASE3","title":"Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2021-01-15","conditions":"Breast Cancer","enrollment":60},{"nctId":"NCT02545231","phase":"PHASE4","title":"Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2013-02","conditions":"Atherosclerosis, Neointima, Angina","enrollment":1000},{"nctId":"NCT01890967","phase":"PHASE2","title":"A Study of LY3015014 in Participants With High Cholesterol","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-06","conditions":"Hypercholesterolemia","enrollment":527},{"nctId":"NCT02290106","phase":"NA","title":"Effects of Pitavastatin on Insulin Sensitivity and Liver Fat","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-03-02","conditions":"Obesity, Fatty Liver, Nonalcoholic","enrollment":50},{"nctId":"NCT03606824","phase":"NA","title":"Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)","status":"UNKNOWN","sponsor":"Shaochun.Li","startDate":"2019-03-25","conditions":"Dyslipidemia, Subclinical hypothyroïdism, Statin","enrollment":248},{"nctId":"NCT02442700","phase":"PHASE4","title":"Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2014-05","conditions":"HIV, Dyslipidemia","enrollment":24},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT01871792","phase":"PHASE4","title":"Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction","status":"UNKNOWN","sponsor":"Gachon University Gil Medical Center","startDate":"2013-06","conditions":"Contrast-induced Nephropathy","enrollment":404}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo (for Pitavastatin)","genericName":"Placebo (for Pitavastatin)","companyName":"JW Pharmaceutical","companyId":"jw-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}